Clinical

Dr Baljević discusses unmet needs that are typically seen in the management of MM.

Dr Brinton highlights the importance of adjunct therapies in LDL management.

Dr Riddock explains how the ASCVD treatment landscape lends itself to initiation of therapy beyond statins in the inpatient setting.

A simple score can identify the patients at risk of severe infection within 4 months of initiating treatment, highlighting candidates to be treated with prophylactic antibiotics.

A multitrait model of corneal parameters was effective in identifying new keratoconus risk loci, resulting in enhanced polygenic risk score models.

The findings suggest that the tool can be used to not only assess cognitive impairment in Huntington disease (HD) but also to detect brain atrophy patterns associated with cognitive status in these patients.

Aldo-keto reductase 1C3 (AKR1C3) has been identified as a potential biomarker and target in several cancers, and a recent study found it to be a potential biomarker in T acute lymphoblastic leukemia/lymphoma (T-ALL).

Chronic kidney disease is a common complication in multiple myeloma, and a recent study found it is safe to treat this patient population with autologous stem cell transplantation.

Researchers outlined 3 mechanisms in which PM2.5 induces asthma, all of which they say are tied to oxidative stress balance.

A review of 41 articles indicated that leveraging zinc supplementation in patients with sickle cell disease (SCD) is a safe and potentially effective approach for these patients.

Mesenchymal stem cells are known to promote tumor growth and metastasis in multiple myeloma (MM), but a recent study found they may also inhibit the effects of the corticosteroid dexamethasone, a common medication for the hematologic malignancy.

Patients with reduced DNA mismatch repair protein expression were more likely to respond to immune checkpoint inhibitors (ICIs), although this study had a small sample size.

Dr Lopes, OB-GYN and payer, discusses a focus on screening and prevention and availability of contraception among health plans in women’s health.

Ayman Al-Hendy, MD, PhD and Maria Lopes, MD, MS discuss common concerns that women seek care for during their reproductive years, including uterine fibroids, endometriosis, and unintended pregnancy.

Monitoring glycemia in chronic kidney disease comes with challenges, but emerging strategies warrant more research in this patient population.

A new review article shows positive trends in survival, as scientists better understand the different types and symptoms of pulmonary arterial hypertension (PAH).

Interviewing both patients and providers, researchers found that while having effective treatments for hidradenitis suppurativa (HS) took precedence across the board, some priorities varied among the 2 groups.

Key opinion leaders discuss navigation through challenges with appropriate coding for TRD treatment.

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

Eliot Brinton, MD, provides a warning concerning “maximally-tolerated statin dosing” and provides general guidance for optimal dosing.

Ian Riddock, MD, describes the high-risk patient with ASCVD that is appropriate for early intensive lipid lowering.

Dr Richter delves into how we can better educate patients and physicians on RWE to improve decision-making.

The panel moves the discussion to non-comparative RWE and how that can play a part in their decision-making for MM therapy.

CDC launches a new center to forecast infectious diseases; Alabama reaches settlement with opioid manufacturers; lack of diversity seen in Alzheimer disease trials.

With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.